Navigation Links
ArborGen and Senesco Announce Wood Quality Results
Date:7/7/2009

ng its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of Senesco to consummate a financing; the development of Senesco's gene technology; the approval of Senesco's patent applications; the successful implementation of Senesco's research and development programs and joint ventures; the success of Senesco's license agreements; the acceptance by the market of Senesco's products; success of Senesco's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, Senesco's ability to meet its funding milestones under its financing transaction, Senesco's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in Senesco's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Senesco's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Senesco undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Senesco Investor Contact:
    Brian Ritchie
    FD
    Phone: (212) 850-5600
    E-mail: brian.ritchie@fd.com

    ArborGen Contact:
    Nancy M. Hood
    Director of Communication & Public Affairs
    Phone: (843) 851-5077
    Cell: (843) 323-1509
    E-mail: nmhood@arborgen.com

'/>"/>
SOURCE ArborGen, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
3. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
4. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
5. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
6. Senesco Technologies to Present at BIO 2008 Business Forum
7. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
8. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
9. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
10. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Spain and Latin American countries have an oppor... sectors. Researchers from the University of Valen...tion, have studied the productive fabric of the Sp...that Spain,s food and plant sectors have more clou...otechnology as applied to food and plants has been...
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-FirstC...MTA: CTIC) announced today that the Ninth Circuit ...der and ruled that CTI should be allowed to pursue... the case back to the District Court for trial. C... former third-party reimbursement consultant for C...
(Date:11/19/2009)..., , SEATTLE, Nov. 19 /PRNewswire-FirstCall/...unced unaudited financial results for the third qu...hs ended September 30, 2009, Omeros reported a net...ared to a net loss of $7.4 million, or $2.54 per s...nths ended September 30, 2009, the Company reporte...
(Date:11/19/2009)..., , MALVERN, Pa. and WALTHAM, Mass., No...(AMR) and Decision Resources find that the leading...monia in Europe is broad-spectrum activity against... the variety of organisms that can cause nosocomia...hat they look primarily for agents that provide ap...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...d line HRPC patients on TPI 287 show clinical bene...cals, Inc. (Nasdaq: TPPH ) announced today financ...26, 2007. The net loss for the third quarter of 2...pares to a net loss for the third quarter of 2006 ...he net loss for the third,quarter of 2007 and 2006...
...ov. 4 Scientists at Monsanto,Company working in c...novative and precise approach to protect crops aga...a Nobel Prize winning discovery. The,technology is...d option to,protect crop yields and present anothe... the world,s growing food, feed and fuel demands. ...
.... 2 Brinks Hofer Gilson & Lione, one of the,large...tates, is pleased to,announce that Meredith Martin...late Group, has been appointed chair of the Amicus...aw Association (AIPLA). AIPLA is a national bar a... lawyers, involved in the practice of patent, trad...
Other Biology Technology:Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 2Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 3Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 4Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 5Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 6Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 7Monsanto and Devgen Describe New Approach to Insect-Protection 2Monsanto and Devgen Describe New Approach to Insect-Protection 3Meredith Martin Addy Named Chair of AIPLA's Amicus Committee 2
(Date:11/20/2009)...AMPAIGN, Ill. In a new study, researchers report ...kers can have a helpful, or harmful, effect on the... The study, which appears in the journal Circulat...t both the alpha- and beta-receptors on the heart ... while those that target only the beta-receptors c...
(Date:11/19/2009)...DISON This week, scientists are revealing the gen...e cereal crops. Corn, or maize, has one of the mos...versity of Wisconsin-Madison genomicist David Schw...article in the journal Science . , "The maize g...d dead-ends that have troubled would-be sequencers...
(Date:11/19/2009)... a massive survey of genetic diversity in maize, a...tates, have developed a gene map that should pave ...t is a major source of food, fuel, animal feed and...l type of gene map known as a haplotype map, chart...enome of 27 inbred lines of maize. The research te...
Breaking Biology News(10 mins):Carvedilol shown to have unique characteristics among beta blockers 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Cooling treatment after cardiac arrest is cost effective Penn study shows 54589 1Licensed Drug and Alcohol Counselor Offers Minimal Cost On Line Guidance to Freedom from Addiction 54586 1Licensed Drug and Alcohol Counselor Offers Minimal Cost On Line Guidance to Freedom from Addiction 54586 2Cognitive behavioral therapy improves sleep and pain in people with osteoarthritis 54582 1Cognitive behavioral therapy improves sleep and pain in people with osteoarthritis 54582 2Cognitive behavioral therapy improves sleep and pain in people with osteoarthritis 54582 3
...Nick Dixon at the Research School of Chemistry at ...e of the great DNA mysteries. For more than 20 yea... last step in the copying of DNA in cells that are...blished in the prestigious international journal C...y a large molecular machine called the replisome. ...
...uth to avoid smiling in public in order to hide th...ly, invasive as well as costly treatment options, ... only treatment options to help these individuals ...However, Kim L. Capehart, DDS, MBA, AGD member and... procedure he used on a patient helped significant...
...c controls which cause trees to stop growing and g...at causes them to begin flowering and produce seed... genetics of tree growth. , The findings were made...cultural Sciences, Oregon State University and two...Science. They represent a significant fundamental ...
Other Biology News:ANU scientists crack DNA replication mystery 2Tetracycline plus teeth equal gray smile 2Tetracycline plus teeth equal gray smile 3Discovery may speed forest biotechnology 2Discovery may speed forest biotechnology 3
10% BSA in TBS from Upstate
Mouse Anti-Bovine Complex IV Monoclonal Antibody, Unconjugated, Clone 31E91B82G9 from MitoScience LLC
Anti-Tropomyosin 4 Antibody, Unconjugated from CHEMICON
Mouse Anti-Human p53, wild & mutant, aa 19-26 Monoclonal Antibody, Unconjugated, Clone DO-7 from CHEMICON
Biology Products: